Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
N Engl J Med ; 362(24): 2282-94, 2010 Jun 17.
Article in English | MEDLINE | ID: mdl-20554983

ABSTRACT

BACKGROUND: The most effective highly active antiretroviral therapy (HAART) to prevent mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) in pregnancy and its efficacy during breast-feeding are unknown. METHODS: We randomly assigned 560 HIV-1-infected pregnant women (CD4+ count, > or = 200 cells per cubic millimeter) to receive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34 weeks' gestation through planned weaning by 6 months post partum. A total of 170 women with CD4+ counts of less than 200 cells per cubic millimeter received nevirapine plus zidovudine-lamivudine (the observational group). Infants received single-dose nevirapine and 4 weeks of zidovudine. RESULTS: The rate of virologic suppression to less than 400 copies per milliliter was high and did not differ significantly among the three groups at delivery (96% in the NRTI group, 93% in the protease-inhibitor group, and 94% in the observational group) or throughout the breast-feeding period (92% in the NRTI group, 93% in the protease-inhibitor group, and 95% in the observational group). By 6 months of age, 8 of 709 live-born infants (1.1%) were infected (95% confidence interval [CI], 0.5 to 2.2): 6 were infected in utero (4 in the NRTI group, 1 in the protease-inhibitor group, and 1 in the observational group), and 2 were infected during the breast-feeding period (in the NRTI group). Treatment-limiting adverse events occurred in 2% of women in the NRTI group, 2% of women in the protease-inhibitor group, and 11% of women in the observational group. CONCLUSIONS: All regimens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%. (ClinicalTrials.gov number, NCT00270296.)


Subject(s)
Antiretroviral Therapy, Highly Active , Breast Feeding , HIV Infections/transmission , HIV-1 , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/drug therapy , Adult , Antiretroviral Therapy, Highly Active/adverse effects , CD4 Lymphocyte Count , Female , Follow-Up Studies , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV-1/genetics , HIV-1/isolation & purification , Humans , Infant , Infant, Newborn , Male , Neutropenia/chemically induced , Nevirapine/therapeutic use , Patient Compliance , Pregnancy , RNA, Viral/blood , Risk Factors , Viral Load/drug effects , Young Adult , Zidovudine/therapeutic use
3.
Cancer Res ; 61(13): 5028-37, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11431337

ABSTRACT

A common polymorphism in the 3' untranslated region of the stromal cell-derived factor 1 (also called pre-B-cell-stimulating factor) beta gene transcript, termed SDF1-3'A, has been associated with an increased risk of non-Hodgkin's lymphoma (NHL) in HIV-1-infected, but not in uninfected, individuals. Because the gene variation is located within the 3' untranslated region, the SDF1-3'A may influence the abundance of SDF-1 mRNA, possibly up-regulating the chemokine expression especially in the presence of HIV-1. In the current study, we investigated the levels of SDF-1 mRNA in peripheral blood mononuclear cells and HIV-1 viral load in 84 HIV-1-infected children (0.7 to 18 years of age; median, 5.8), including 12 children who developed NHL during their illnesses (AIDS-NHL group; 8 with SDF1-3'A, 4 with SDF1-wild-type). High level SDF-1 expression was observed in 15 of 34 children with SDF1-3'A as compared with 10 of 50 with wild type (P < 0.03). More notably, the children with AIDS-NHL had significantly elevated levels of SDF-1 mRNA in peripheral blood mononuclear cells, obtained at the time of presentation in 10 children and 8.5 to 19.4 months before (median, 15 months) in 7 children, as compared with the children in the non-NHL group (P < 0.00001). The amounts of cell-associated HIV-1 DNA and singly spliced HIV-1 mRNA were significantly greater in children with AIDS-NHL than those with non-NHL AIDS (P = 0.0052 and 0.011, respectively; stratified by antiretroviral treatment regimen), whereas their serum HIV-1 RNA levels were comparable. Overexpression of SDF-1 and aberrant HIV-1 expression in circulating lymphocytes appear to be linked to the development of AIDS-lymphoma. Additional studies are required to determine whether excessive SDF-1, together with virally encoded factors, is directly involved in the pathogenesis of AIDS-lymphoma.


Subject(s)
Chemokines, CXC/genetics , HIV Infections/blood , HIV-1 , Lymphoma, AIDS-Related/blood , Lymphoma, Non-Hodgkin/blood , RNA, Messenger/blood , Adolescent , Chemokine CXCL12 , Chemokines, CXC/biosynthesis , Child , Child, Preschool , DNA, Viral/blood , Female , HIV Infections/complications , HIV Infections/genetics , Herpesvirus 4, Human/genetics , Humans , Infant , Lymphoid Tissue/metabolism , Lymphoma, AIDS-Related/genetics , Lymphoma, Non-Hodgkin/genetics , Lymphoma, Non-Hodgkin/virology , Male , RNA, Messenger/metabolism , Viral Load
4.
Pediatrics ; 102(1 Pt 1): 101-9, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9651421

ABSTRACT

BACKGROUND: Indinavir, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, is approved for the treatment of HIV infection in adults when antiretroviral therapy is indicated. We evaluated the safety and pharmacokinetic profile of the indinavir free-base liquid suspension and the sulfate salt dry-filled capsules in HIV-infected children, and studied its preliminary antiviral and clinical activity in this patient population. In addition, we evaluated the pharmacokinetic profile of a jet-milled suspension after a single dose. METHODS: Previously untreated children or patients with progressive HIV disease despite antiretroviral therapy or with treatment-associated toxicity were eligible for this phase I/II study. Three dose levels (250 mg/m2, 350 mg/m2, and 500 mg/m2 per dose given orally every 8 h) were evaluated in 2 age groups (<12 years and >/=12 years). Indinavir was initially administered as monotherapy and then in combination with zidovudine and lamivudine after 16 weeks. RESULTS: Fifty-four HIV-infected children (ages 3.1 to 18.9 years) were enrolled. The indinavir free-base suspension was less bioavailable than the dry-filled capsule formulation, and therapy was changed to capsules in all children. Hematuria was the most common side effect, occurring in 7 (13%) children, and associated with nephrolithiasis in 1 patient. The combination of indinavir, lamivudine, and zidovudine was well tolerated. The median CD4 cell count increased after 2 weeks of indinavir monotherapy by 64 cells/mm3, and this was sustained at all dose levels. Plasma ribonucleic acid levels decreased rapidly in a dose-dependent way, but increased toward baseline after a few weeks of indinavir monotherapy. CONCLUSIONS: Indinavir dry-filled capsules are relatively well tolerated by children with HIV infection, although hematuria occurs at higher doses. Future studies need to evaluate the efficacy of indinavir when combined de novo with zidovudine and lamivudine.


Subject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Indinavir/therapeutic use , Adolescent , Adult , Biological Availability , CD4 Lymphocyte Count , Capsules , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , HIV/drug effects , HIV Infections/blood , HIV Infections/virology , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/pharmacokinetics , Humans , Indinavir/adverse effects , Indinavir/pharmacokinetics , Infant , Lamivudine/adverse effects , Lamivudine/pharmacokinetics , Lamivudine/therapeutic use , Male , Suspensions , Viral Load , Virus Replication/drug effects , Zidovudine/adverse effects , Zidovudine/pharmacokinetics , Zidovudine/therapeutic use
6.
Lippincotts Prim Care Pract ; 3(1): 93-107, 1999.
Article in English | MEDLINE | ID: mdl-10214209

ABSTRACT

Lower respiratory tract infections in children are common and vary from relatively self-limited courses to life-threatening presentations. Recognition of disease patterns as they relate to age, sex, race, season, geography, environmental, and socioeconomic conditions is crucial in determining appropriate differential diagnosis and treatment strategies. The majority of children with respiratory infections will present to the primary care provider in an office setting and less frequently may require immediate referral from home or the outpatient setting to an emergency department. For children with recurrent or chronic respiratory infections, referral to a subspecialist may also be necessary. Primary providers are key in determining the extent of diagnostic effort, interventions, referrals, repeat evaluations, and in reinforcing treatment plans with children and their families.


Subject(s)
Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/therapy , Adolescent , Adult , Age Factors , Bronchiolitis/diagnosis , Bronchiolitis/microbiology , Bronchiolitis/therapy , Bronchitis/diagnosis , Bronchitis/microbiology , Bronchitis/therapy , Child , Child, Preschool , Croup/diagnosis , Croup/microbiology , Croup/therapy , Diagnosis, Differential , Humans , Infant , Primary Health Care/methods , Respiratory Tract Infections/microbiology
7.
J Infect Dis ; 183(7): 1116-20, 2001 Apr 01.
Article in English | MEDLINE | ID: mdl-11237839

ABSTRACT

Virologic and immunologic responses were examined for 33 human immunodeficiency virus (HIV)-infected children who participated for > or = 96 weeks in a phase 1/2 protocol of 16 weeks of indinavir monotherapy, followed by the addition of zidovudine and lamivudine. At week 96, a median increase of 199 CD4+ T cells/microL and a median decrease of 0.74 log(10) HIV RNA copies/mL were observed. The relationship between control of viral replication and CD4) T cell count was examined. Patients were categorized into 3 response groups on the basis of duration and extent of control of viral replication. Of 21 children with a transient decrease in virus load of > or = 0.7 log(10) HIV RNA copies/mL from baseline, 7 experienced sustained increases in CD4+, CD4+ CD45RA+, and CD4+ CD45RO+ T cell counts. CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV , Indinavir/therapeutic use , Lamivudine/therapeutic use , Zidovudine/therapeutic use , Adolescent , CD4 Antigens/analysis , CD4 Lymphocyte Count , Child , Child, Preschool , Drug Therapy, Combination , Female , Follow-Up Studies , HIV/isolation & purification , HIV Infections/immunology , HIV Infections/virology , Humans , Leukocyte Common Antigens/analysis , Male , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , RNA, Viral/analysis , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL